Sugi Predict

Sugi Predict / Compounds / SCHEMBL43071

SCHEMBL43071

SCHEMBL43071

O=C(O)CN1C(=O)OC[C@H]1c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GLS O94925 4/20 0.51
▸ NPC1 O15118 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ HDAC1 Q13547 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ AVPR1A P37288 1/20 0.41
▸ IDH1 O75874 2/20 0.41
▸ SCD5 Q86SK9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42224 1.00 GLS (0.51) GLSNPC1LMNATP53HPGD
SCHEMBL1285658 1.00 GLS (0.51) GLSNPC1LMNATP53HPGD
SCHEMBL15743848 0.88 GLS (0.49) GLSNPC1LMNATP53HPGD
SCHEMBL9036084 0.88 GLS (0.49) GLSNPC1LMNATP53HPGD
SCHEMBL42111 0.88 GLS (0.49) GLSNPC1LMNATP53HPGD
SCHEMBL15743835 0.88 GLS (0.49) GLSNPC1LMNATP53HPGD
SCHEMBL42681 0.88 GLS (0.49) GLSNPC1LMNATP53HPGD
SCHEMBL9036013 0.86 TSHR (0.43) GLSNPC1LMNATP53HPGD
SCHEMBL9035836 0.86 HTT (0.43) GLSLMNASMN1; SMN2ALDH1A1HTT
SCHEMBL14665118 0.85 GLS (0.49) GLSNPC1LMNATP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117417272-A Preparation method of Boc-D-isoleucine 上海海皋科技有限公司 2024-01-19 — — CN claimed
CN-111295373-B Compositions and methods for treating brain injury 阿泽凡药物公司 2024-12-10 — — CN disclosed
CN-117417272-B Preparation method of Boc-D-isoleucine 上海海皋科技有限公司 2024-08-13 — — CN disclosed
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2024-04-11 — — US disclosed
CN-117417272-A Preparation method of Boc-D-isoleucine 上海海皋科技有限公司 2024-01-19 — — CN disclosed
US-20230123729-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2023-04-20 — — US disclosed
US-11628160-B2 Compositions and methods for treating brain injury AZEVAN PHARMACEUTICALS, INC. (US) 2023-04-18 — — US disclosed
CN-106459021-B Compositions and methods for treating neurodegenerative diseases 阿泽范药品公司 2023-04-07 — — CN disclosed
EP-3122743-B1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2022-11-09 — — EP disclosed
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases AZEVAN PHARMACEUTICALS, INC. (US) 2022-05-03 — — US disclosed
US-20090170825-A1 BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS AZEVAN PHARMACEUTICALS, INC. 2009-07-02 — — US disclosed
WO-2009055696-A1 CARBACEPHEM β-LACTAM ANTIBIOTICS ACHAOGEN, INC. (US) 2009-04-30 — — WO disclosed
US-20080280870-A1 Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists AZEVAN PHARMACEUTICALS, INC. 2008-11-13 — — US disclosed
EP-1910346-A2 BETA-LACTAMYL PHENYLALANINE, CYSTEINE, AND SERINE VASOPRESSIN ANTAGONIST Azevan Pharmaceuticals, Inc. (US) 2008-04-16 — — EP disclosed
WO-2008034032-A2 BETA-LACTAM CANNABINOID RECEPTOR MODULATORS AZEVAN PHARMACEUTICALS, INC. (US) 2008-03-20 — — WO disclosed
EP-1868434-A2 BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS Azevan Pharmaceuticals, Inc. (US) 2007-12-26 — — EP disclosed
WO-2007109615-A2 β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS AZEVAN PHARMACEUTICALS, INC. (US) 2007-09-27 — — WO disclosed
WO-2007011878-A2 BETA-LACTAMYL PHENYLALANINE, CYSTEINE, AND SERINE VASOPRESSIN ANTAGONISTS AZEVAN PHARMACEUTICALS, INC. (US) 2007-01-25 — — WO disclosed
WO-2006102308-A2 BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS AZEVAN PHARMACEUTICALS, INC. (US) 2006-09-28 — — WO disclosed
WO-2006102283-A2 BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS AZEVAN PHARMACEUTICALS, INC. (US) 2006-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY FABP7, PYGB, CHAT GLS 1719/4885NPC1 705/4885LMNA 451/4885
US-20080280870-A1 Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists AVPR2, AVPR1A, AVPR1B GLS 519/4885NPC1 2491/4885LMNA 3319/4885
US-20090170825-A1 BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS GABBR1, GABBR2, ALAD GLS 1608/4885NPC1 2949/4885LMNA 1471/4885
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases HTT, AVPR2, AVPR1B GLS 775/4885NPC1 253/4885LMNA 1342/4885
US-20230123729-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES HTT, AVPR2, AVPR1B GLS 775/4885NPC1 253/4885LMNA 1342/4885
US-11628160-B2 Compositions and methods for treating brain injury FABP7, PYGB, CHAT GLS 1719/4885NPC1 705/4885LMNA 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.